← All trials
NCT02082769
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2011
- Primary completion
- Oct 1, 2013
- Completion date
- Oct 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 504
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- People's Liberation Army of ChinaLead sponsor
- Qingdao UniversityOverall official - principal investigator
- LanZhou UniversityOverall official - principal investigator
- Shaanxi Provincial People's HospitalOverall official - principal investigator
- Zhejiang UniversityOverall official - principal investigator
- Luoyang Orthopedic-Traumatological HospitalOverall official - principal investigator
- Guangxi Medical UniversityOverall official - principal investigator
- Jilin UniversityOverall official - principal investigator
- Shantou UniversityOverall official - principal investigator
- Shanxi Medical UniversityOverall official - principal investigator
- Hacettepe UniversityOverall official - principal investigator
- Qingdao Shengbang Pharmaceutical Co., Ltd.Collaborator
- Jiao Tong UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.